GLP-1 Receptor Agonists Associated with Reduced Metastatic Progression in Obesity-Related Cancers (ascopost.com)

• GLP-1 RA use associated with lower metastasis rates in obesity-related cancers
• Real-world evidence supports design of clinical trials in Ireland
• Potential new avenue for cancer prevention and treatment

"Real-world data suggests that GLP-1 receptor agonists (GLP-1 RAs) may reduce metastatic progression in certain obesity-related cancers. These findings provide direct evidence to inform clinical trial design and could improve cancer care for Irish patients. The observational study highlights a potential additional benefit of these diabetes and weight-loss drugs beyond metabolic control."